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918 LETTERS TO THE EDITORthe most well-esteemed equipment careful calibration of the
calibrators is mandatory (6). We did adopt the principles of
traceability to international standards throughout our
study and on the basis of this our results should be
weighted.
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University of Copenhagen at
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Dear Sir
Assessing lung deposition of inhaled
medications. Consensus statement
from a workshop of the British
Association for Lung Research, held at
the Institute of Biology, London, U.K.
on 17 April 1998. Snell NJC,
Ganderton D. eds. Respir Med 1999;
93: 123–133.cromoglycate were associated with dierences in regional
lung deposition and the decreased penetration seen with
more rapid inspiration was associated with reduced
protection against allergen challenge. The report then goes
on to state that this study correlates well with previous
work using a PK technique, showing that rapid inhalation
of sodium cromoglycate was associated with reduced total
lung deposition. The reference quoted is that of Richards
et al. (2). This in fact shows the complete opposite. The
study showed that the inspiratory flow rates measured of
184+ 14, 101+ 4, 57+ 3 lmin71 gave lung deposition, as
determined by AUC0–240, of 1245+ 220, 657+ 90 and
413+ 69 ngml71min respectively.
The dierences in these studied illustrate the dierences
in the techniques used in drug administration. Laube et al.
used a 1mg pressurized metered dose inhaler (MDI) with
the drug being placed into and inhaled from a 750ml
spacer. In these circumstances optimal lung deposition,
distribution and protection against allergen challenge is
given by slow inspiration. Richards et al. used a dry powder
inhaler, the Spinhaler, and the drug was inhaled from a
gelatine capsule. Using this method of administration,
rapid inspiration provides greater lung deposition and
greater protection. In the first case the particle size
characteristics of the inhaled drug is determined by the
dose size, the nozzle of the metered dose inhaler, and the
spacer. In the second case the particle sizes are largely
determined by the eciency with which the particular
device breaks up the large particles in the capsule into
smaller sizes. This in turn is largely determined by the speed
of inhalation through the device. Thus the two systems are
entirely dierent in the way in which they produce optimal
deposition within the lung. In the case of metered dose
pressurized inhalers, inhalation should be slow, around
30 lmin71. In the case of the Spinhaler, a dry powder
system, inhalation rates in excess of 120 lmin71 are
required.
An additional relevant study in this context is also by
Richards et al. (3,4) which measures the protective eect of
inhaled sodium cromoglycate against AMP-induced
bronchoconstriction using dierent inspiratory flow rates.
The drug was administered with the Spinhaler from gelatine
capsules. The inspiratory flow rates achieved were
221+ 87, 108+ 3 and 59+ 3 lmin71. The lung deposition
was 3318+ 925, 1702+ 378 and 1073+ 218 ngminml71.
The PC20AMP at each inspiratory rate were 136, 40 and 15.
Again, using a patient driven inhaler more rapid inhalation
gave greater lung deposition and greater protection against
challenge.
The report concludes that in vitro measurements of
aerosol fine particle fraction has a key role to play in the
development of new pharmaceutical products and in
quality control. A multistage apparatus should be used
over the particle size range 0?5–5?0mm. In Europe, apart
from Germany, the most widely used inhaled product of
sodium cromoglycate is the 5mgdose71 MDI. Applying
these criteria to the data provided in the paper by Newman
et al. (4), using the 5mg MDI, the lung deposition as
estimated by the fine particle fraction would be 15% of the
inhaled dose. That demonstrated by the radiolabelledIn the discussion section of this report, in which the
relationship between lung deposition of inhaled drugs and
clinical ecacy is discussed, there is an error in the
interpretation of one of the papers dealing with inhaled
sodium cromoglycate.
In the reference to the study by Laube et al. (1) it is stated
correctly that dierences in the rate of inhalation of sodium# 2000 HARCOURT PUBLISHERS LTD
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et al. (5), which used urinary output, calculated the
percentage of the inhaled dose delivered to the lung at
between 2 and 3%. In view of the disparity between these
three sets of figures, it may still be necessary to carry out
controlled clinical trials with each new inhaled product in
order to determine clinical ecacy and bioequivalence. The
use of in vitro particle size estimation may be suitable for
quality control purposes as long as it is recognized that it
does not reflect lung deposition or distribution or implied
bioavailability.
A. M. EDWARDS
University Medicine, Southampton General Hospital,
Southampton, U.K.
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Sir,
Response to letter from
Dr A. M. Edwards in assessing
lung deposition of
inhaled medications.
(Respir Med 1999; 93: 123–133)shows the diculty in pulling together key points from a
variety of inputs at a workshop. It is clear from numerous
publications that lung deposition from breath-actuated dry-
powder inhalers increases with increasing inspiratory flow
rate, in contra-distinction to the situation with metered
dose inhalers.
We entirely agree that in vitro measurements of aerosol
fine particle fraction are not reliably predictive of lung
deposition, and we made the point that their principal value
was in quality control. The data Dr Edwards quotes
support our statement that ‘The FPF (fine particle fraction)
measured by in vitro methods generally overestimates the
lung deposition measured using in vivo systems’. The
disparity between the two in vivo measurements he quotes
(radiolabelled lung deposition and urinary output) is
dicult to evaluate since they were not made in the same
subjects under the same conditions. Bioequivalence could
be established (in theory) by comparing radiolabelled lung
deposition of two dierent products, or urinary excretion of
two dierent products, but not by comparing radiolabelled
deposition of one with urinary output of another; whereas
the ‘gold standard’ for comparing clinical ecacy is to
carry out a clinical trial.
Our consensus statement was intended to summarize the
current state-of-the-art and clarify the value and correct use
of the various methods of estimating lung deposition of
inhaled medications, and to review the potential for new or
improved methods to increase the accuracy of these
estimations, with the possibility that eventually surrogate
in vivo methods might be able to replace some of the clinical
testing required today.
N.J.C. SNELL* AND D. GANDERTON{
* The Old School House, Pishill,
Henley-on-Thames RG9 6HJ and
{Vectura Ltd, University of Bath Campus, BA2 7AY, U.K.We thank Dr Edwards for his interest in our consensus
statement. He is correct in his comment; the reference we
quoted was not appropriate to the point being made, anddoi:10.1053/rmed.2000.0833
Dear Editor
Bovine TB alertKoch’s discovery of the tubercle bacillus in 1882, and of
‘Old Tuberculin’ soon afterwards, paved the way for cattle
TB control schemes by test and slaughter or reactors. His
mistaken view that bovine TB was not a risk to man, at
least led to exhaustive studies of TB. Bang pioneered such
work in Denmark and noted in 1892 [cited in Francis (1) ]:
It is found that the tuberculin test is no more perfect
than are other things in this world. Sometimes it fails.
Animals with a very real degree of tuberculosis will
sometimes fail to react, and the same applies to animals
with a very slight degree of the disease. Further, a
positive reaction has been observed several times in
animals in which no tuberculous changes were found on# 2000 HARCOURT PUBLISHERS LTD
